New scan agent could spot pancreatic cancer more clearly
NCT ID NCT07597772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new contrast agent called 68Ga-NODAGA-SNA014, which targets a protein (CLDN18.2) found on some pancreatic cancer cells. The agent is used with PET/CT scans to see if it can safely and accurately highlight tumors. The study involves 12 adults with pancreatic cancer and focuses on safety and how well the agent binds to cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?